Comparative Pharmacology
Head-to-head clinical analysis: ALMOTRIPTAN MALATE versus MAXALT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALMOTRIPTAN MALATE versus MAXALT.
ALMOTRIPTAN MALATE vs MAXALT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT1B/1D receptor agonist; cranial vasoconstriction and inhibition of trigeminal nerve transmission.
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibits trigeminal nerve signaling.
12.5 mg orally at onset of migraine; may repeat after 2 hours if headache recurs. Maximum 25 mg/day.
5 mg or 10 mg orally at onset of migraine; maximum 30 mg in 24 hours (two doses with at least 2 hours between them).
None Documented
None Documented
Terminal elimination half-life: 3-4 hours. In patients with hepatic impairment, half-life may be prolonged (up to 6-7 hours), necessitating dose adjustment.
2-3 hours in plasma; clinical effect correlates with distribution to CNS rather than plasma half-life.
Approximately 70% renal excretion (40% unchanged, 30% as metabolites), 30% fecal/biliary elimination.
Renal (60% as unchanged drug and metabolites) and fecal (40% primarily as metabolites).
Category C
Category C
Antimigraine Agent
Antimigraine Agent